Prevalence of Antimicrobial Resistance among Clinical Isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance Study
Prevalence of Antimicrobial Resistance among Clinical Isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance Study
复制标题
DOI：
10.1128/aac.05823-11
复制
发表时间：
2012-03-01
影响因子：
4.9
通讯作者：
Zhanel, George G.
中科院分区：
文献类型：
--
作者：
Karlowsky, James A.;Walkty, Andrew J.;Zhanel, George G.
脆弱拟杆菌组的临床分离株（n = 387）是从 2010 年至 2011 年在加拿大 9 家医院就诊的患者中收集的，并使用临床和实验室标准研究所 (CLSI) 肉汤微量稀释法测试了对 10 种抗菌药物的敏感性。脆弱拟杆菌 (59.9%)、卵形拟杆菌 (16.3%) 和多形拟杆菌 (12.7%) 占收集的分离株的 90%。总体敏感性百分比如下：甲硝唑99.7%； 99.5%，哌拉西林-他唑巴坦； 99.2%，亚胺培南； 97.7%，厄他培南； 92.0%，多尼培南； 87.3%，阿莫西林克拉维酸； 80.9%，替加环素； 65.9%，头孢西丁； 55.6%，莫西沙星； 52.2%是克林霉素。 B. thetaiotaomicron (n = 49, 24.5%)、Parabacteroides distasonis/P 对头孢西丁、克林霉素和莫西沙星的敏感性百分比最低。 merdae (n = 11, 9.1%) 和 B. ovatus (n = 63, 31.8%)。一种分离株（B. thetaiotaomicron）对甲硝唑耐药，两种分离株（均为脆弱拟杆菌）对哌拉西林-他唑巴坦和亚胺培南均耐药。自近 20 年前最近发表的描述加拿大脆弱拟杆菌群分离株的监测研究以来（A.-M. Bourgault 等人，Antimicrob. Agents Chemother. 36:343-347, 1992），阿莫西林克拉维酸的耐药率已从 0.8% (1992) 增加到 6.2% (2010-2011)，而克林霉素，从 9% (1992) 到 34.1% (2010-2011)。
Clinical isolates of the Bacteroides fragilis group (n = 387) were collected from patients attending nine Canadian hospitals in 2010-2011 and tested for susceptibility to 10 antimicrobial agents using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. B. fragilis (59.9%), Bacteroides ovatus (16.3%), and Bacteroides thetaiotaomicron (12.7%) accounted for similar to 90% of isolates collected. Overall rates of percent susceptibility were as follows: 99.7%, metronidazole; 99.5%, piperacillin-tazobactam; 99.2%, imipenem; 97.7%, ertapenem; 92.0%, doripenem; 87.3%, amoxicillin-clavulanate; 80.9%, tigecycline; 65.9%, cefoxitin; 55.6%, moxifloxacin; and 52.2%, clindamycin. Percent susceptibility to cefoxitin, clindamycin, and moxifloxacin was lowest for B. thetaiotaomicron (n = 49, 24.5%), Parabacteroides distasonis/P. merdae (n = 11, 9.1%), and B. ovatus (n = 63, 31.8%), respectively. One isolate (B. thetaiotaomicron) was resistant to metronidazole, and two isolates (both B. fragilis) were resistant to both piperacillin-tazobactam and imipenem. Since the last published surveillance study describing Canadian isolates of B. fragilis group almost 20 years ago (A.-M. Bourgault et al., Antimicrob. Agents Chemother. 36:343-347, 1992), rates of resistance have increased for amoxicillin-clavulanate, from 0.8% (1992) to 6.2% (2010-2011), and for clindamycin, from 9% (1992) to 34.1% (2010-2011).